SG11201703006QA - Monoclonal ανίί-gpc-l antibodies and uses thereof - Google Patents

Monoclonal ανίί-gpc-l antibodies and uses thereof

Info

Publication number
SG11201703006QA
SG11201703006QA SG11201703006QA SG11201703006QA SG11201703006QA SG 11201703006Q A SG11201703006Q A SG 11201703006QA SG 11201703006Q A SG11201703006Q A SG 11201703006QA SG 11201703006Q A SG11201703006Q A SG 11201703006QA SG 11201703006Q A SG11201703006Q A SG 11201703006QA
Authority
SG
Singapore
Prior art keywords
ανίί
gpc
monoclonal
antibodies
monoclonal ανίί
Prior art date
Application number
SG11201703006QA
Inventor
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Bradley Walsh
Sandra Wissmueller
Original Assignee
Minomic Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic Internat Ltd filed Critical Minomic Internat Ltd
Publication of SG11201703006QA publication Critical patent/SG11201703006QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201703006QA 2014-10-23 2014-10-23 Monoclonal ανίί-gpc-l antibodies and uses thereof SG11201703006QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2014/000999 WO2016061608A1 (en) 2014-10-23 2014-10-23 Monoclonal ανίί-gpc-l antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201703006QA true SG11201703006QA (en) 2017-05-30

Family

ID=55759935

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703006QA SG11201703006QA (en) 2014-10-23 2014-10-23 Monoclonal ανίί-gpc-l antibodies and uses thereof

Country Status (11)

Country Link
US (1) US10577418B2 (en)
EP (1) EP3209686B1 (en)
JP (1) JP6749901B2 (en)
KR (1) KR102249981B1 (en)
CN (1) CN107108734B (en)
AU (1) AU2014409558B2 (en)
CA (1) CA2964179C (en)
DK (1) DK3209686T3 (en)
ES (1) ES2778100T3 (en)
SG (1) SG11201703006QA (en)
WO (1) WO2016061608A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138530A (en) * 2015-04-20 2017-12-15 미노믹 인터내셔널 리미티드 Therapeutic antibodies and uses thereof
JPWO2018199318A1 (en) * 2017-04-28 2020-03-12 国立大学法人高知大学 Anti-GPC-1 antibody
CN113784987A (en) * 2019-01-22 2021-12-10 美国政府(由卫生和人类服务部的部长所代表) High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2020007315A (en) * 2019-08-02 2020-01-16 ミノミック インターナショナル リミティド Monoclonal anti-gpc-1 antibodies and uses thereof
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622836A (en) * 1989-05-24 1997-04-22 The University Of Sydney Monoclonal antibodies which recognize malignant cells from bladder carcinomas
JPH05504466A (en) * 1989-05-24 1993-07-15 ザ　セントラル　シドニー　エリア　ヘルス　サービス Monoclonal antibody that recognizes malignant cells from bladder cancer
EP0473651A4 (en) 1989-05-24 1992-10-14 The University Of Sydney Monoclonal antibodies which recognise malignant cells from bladder carcinomas
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
CN101070345B (en) * 2006-05-12 2010-09-29 中国科学院上海生命科学研究院 Anti-prostate-specific-antigen PSA monoclone antibody and its use
AU2015207665B2 (en) * 2014-01-17 2021-04-15 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
ES2805085T3 (en) * 2015-01-16 2021-02-10 Glyp Holdings Pty Ltd Glypican Epitopes and Uses of These
KR20170138530A (en) * 2015-04-20 2017-12-15 미노믹 인터내셔널 리미티드 Therapeutic antibodies and uses thereof

Also Published As

Publication number Publication date
KR20170085051A (en) 2017-07-21
KR102249981B1 (en) 2021-05-11
AU2014409558A1 (en) 2017-05-04
US10577418B2 (en) 2020-03-03
DK3209686T3 (en) 2020-03-16
EP3209686A4 (en) 2018-03-07
CN107108734A (en) 2017-08-29
AU2014409558A8 (en) 2019-08-08
ES2778100T3 (en) 2020-08-07
AU2014409558B2 (en) 2021-08-12
WO2016061608A8 (en) 2017-06-29
CA2964179C (en) 2023-04-11
EP3209686B1 (en) 2019-12-25
CN107108734B (en) 2021-09-14
CA2964179A1 (en) 2016-04-28
JP6749901B2 (en) 2020-09-02
US20180072803A1 (en) 2018-03-15
WO2016061608A1 (en) 2016-04-28
JP2017531442A (en) 2017-10-26
EP3209686A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IL283321A (en) Anti-muc16 antibodies and uses thereof
IL285375A (en) Il-8-binding antibodies and uses thereof
HK1254861A1 (en) Anti-lag3 antibodies and uses thereof
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
IL262095A (en) Anti-pacap antibodies and uses thereof
HK1255067A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en) Anti-interleukin-33 antibodies and uses thereof
IL290457A (en) Antibodies and conjugates thereof
IL247407A0 (en) Anti-egfrviii antibodies and uses thereof
HK1256381A1 (en) Anti-pacap antibodies and uses thereof
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL251001A0 (en) Anti-il-25 antibodies and uses thereof
RS62912B1 (en) Anti-human-her3 antibodies and uses thereof
IL266049A (en) Anti-o1 antibodies and uses thereof
IL266082A (en) Anti-chikv antibodies and uses thereof
IL264417A (en) Anti-o2 antibodies and uses thereof
SG11201703006QA (en) Monoclonal ανίί-gpc-l antibodies and uses thereof
HK1254240A1 (en) Anti-hypusine antibodies and uses thereof